DeNardo S J, DeNardo G L, O'Grady L F, Hu E, Sytsma V M, Mills S L, Levy N B, Macey D J, Miller C H, Epstein A L
Department of Internal Medicine, University of California, Davis Medical Center, Sacramento 95817.
Int J Cancer Suppl. 1988;3:96-101.
Lym-I is a murine IgG2a monoclonal antibody (MAb) that is B-cell specific but has greater avidity for malignant B cells when compared with normal B lymphocytes. It was originally produced by immunizing mice with nuclei of cultured cells from a patient with Burkitt's lymphoma. Ten patients with progressive refractory B-cell malignancies were treated with 131I-labelled Lym-I. Treatment with 131I Lym-I produced complete or partial remissions in 4 patients. Toxicity did not occur or was mild in most patients. The only significant complications included two instances of fistula secondary to necrotic lymphoma and one instance of hypotension. Human antimouse antibodies occurred in only 2 patients after multiple injections of Lym-I antibody. This experience was in contrast to treatment of B-cell malignancies with unconjugated Lym-I alone. Unconjugated Lym-I also caused no significant toxicity but was less effective than 131I Lym-I.
Lym-I是一种鼠源IgG2a单克隆抗体（MAb），它对B细胞具有特异性，但与正常B淋巴细胞相比，对恶性B细胞具有更高的亲和力。它最初是通过用来自一名伯基特淋巴瘤患者的培养细胞核免疫小鼠而产生的。10名进行性难治性B细胞恶性肿瘤患者接受了131I标记的Lym-I治疗。131I Lym-I治疗使4名患者获得完全或部分缓解。大多数患者未出现毒性反应或毒性反应较轻。唯一显著的并发症包括两例坏死性淋巴瘤继发瘘管和一例低血压。多次注射Lym-I抗体后，仅2名患者出现人抗鼠抗体。这一经验与单独使用未结合的Lym-I治疗B细胞恶性肿瘤形成对比。未结合的Lym-I也未引起明显毒性，但效果不如131I Lym-I。
